Name

Addition Therapeutics

Legal name

Addition Therapeutics, Inc.

Website

https://additiontx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Genetic Medicine / RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• RNA therapeutics
• Genetic medicine
• Gene therapy platform
• Lipid nanoparticle delivery
• Genomic medicines

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Development and Licensing: As a clinical-stage genomic medicine company, Addition Therapeutics generates revenue through pharmaceutical partnerships, licensing agreements, and potential milestone payments as pipeline programs advance through development stages. The company has research initiatives with pharmaceutical companies and the Gates Foundation funding specific programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Addition Therapeutics develops the PRINT™ (Precise RNA-Mediated Insertion of Transgenes) platform, an all-RNA, non-viral, lipid nanoparticle (LNP)-based genetic medicine technology that enables precise, site-specific insertion of therapeutic transgenes to a ribosomal DNA safe-harbor site using R2 retrotransposase machinery. The company is advancing a pipeline of PRINTed therapeutic candidates for chronic and rare diseases, including lead programs for a rare obesity indication and Fabry disease, with additional research-stage programs in HIV, ocular disease, and in vivo CAR-T.

Product overview

Addition Therapeutics is advancing the PRINT™ (Precise RNA-Mediated Insertion of Transgenes) platform, an all-RNA, non-viral, LNP-based genetic medicine technology that combines the efficacy and safety of RNA therapeutics with the durability of gene therapies. The company is developing a pipeline of PRINTed therapeutics targeting rare and chronic diseases, including lead programs for a rare obesity indication and Fabry disease, with research collaborations in in vivo CAR-T, HIV (Gates Foundation-funded), and ocular disease programs.

Differentiator

Problem solved

Functional benefit

Brands

• PRINT: Precision RNA-Mediated Insertion of Transgenes - an all-RNA, non-viral, LNP-based genomic medicine platform designed to develop safer, durable, one-time therapies for chronic and rare diseases.

Products and services

• PRINT™ Platform An all-RNA, non-viral, lipid nanoparticle (LNP)-based genetic medicine platform that uses R2 retrotransposase machinery to insert therapeutic transgenes precisely into a ribosomal DNA safe-harbor site, combining the efficacy and safety of RNA therapeutics with the multi-year durability of gene therapies. Offered as a development platform to pharmaceutical partners.
• PRINTed Therapeutics Pipeline A portfolio of genetic medicine candidates developed using the PRINT platform, targeting chronic and rare diseases including rare obesity, Fabry disease, HIV, and ocular diseases.
• Rare Obesity Program Preclinical PRINTed therapeutic candidate for a rare, undisclosed obesity indication designed to provide sustained therapeutic protein expression with single-dose administration.
• Fabry Disease Program PRINTed therapeutic candidate expressing functional α-Gal A enzyme via precise RNA-mediated insertion of the GLA transgene, designed to address the multi-organ impact of Fabry disease with multi-year durability.
• HIV Program

Quantifiable outcome

• Demonstrated >1 year durable protein expression in mice and >6 months in NHPs with flat pharmacokinetics profile
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• University of California, BerkeleycoreStrategic or Co-development PartnerAddition is a spinout of Professor Kathleen Collins' laboratory at UC Berkeley. The foundational technology for PRINT is based on Dr. Collins' retrotransposase expertise, with technology development backed by entrepreneurship funding from the Bakar Fellows Program and an NIH Director's Pioneer Award. Dr. Collins serves on Addition's Board of Directors.
• Bakar LabssupportingStrategic or Co-development PartnerAddition Therapeutics is a tenant at Bakar Labs, UC Berkeley's flagship life science incubator. The company's $100 million funding round was part of the milestone where Bakar Labs companies raised over $1 billion in cumulative funding during its first four years of operation.
• Undisclosed Pharmaceutical CompaniescoreStrategic or Co-development PartnerResearch initiatives with undisclosed pharmaceutical companies have enabled Addition to advance multiple chronic and rare disease PRINTed programs as the company builds a diverse pipeline. The company is also advancing in vivo CAR-T and obesity programs through research initiatives with two top 10 pharmaceutical companies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Beam Therapeutics: Beam Therapeutics develops base editing therapeutics for genetic diseases using lipid nanoparticle delivery, directly comparable to Addition's PRINT platform approach of combining RNA-based delivery with precise genomic modifications. Beam's pipeline in sickle cell disease, alpha-1 antitrypsin deficiency, and other indications overlaps with Addition's rare disease focus.
• Editas Medicine: Editas Medicine develops CRISPR-based gene editing therapeutics for sickle cell disease, hereditary blindness, and other indications. As a foundational gene editing platform company, Editas competes with Addition for genetic disease market share and partnership opportunities.
• Sangamo Therapeutics: Sangamo develops zinc finger nuclease-based gene editing and gene regulation therapeutics for genetic diseases, including Fabry disease programs that directly overlap with Addition's Fabry pipeline. Addition's VP Cost previously held leadership roles at Sangamo.
• Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 therapeutics using LNP delivery for transthyretin amyloidosis, hereditary angioedema, and other indications. Like Addition, Intellia uses non-viral LNP delivery for systemic in vivo gene editing applications.
• CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based therapeutics for hemoglobinopathies, oncology, and regenerative medicine. Addition's CSO previously held scientific leadership roles at CRISPR Therapeutics, and both companies target durable genetic cures through precise genomic modification.
• Verve Therapeutics: Verve Therapeutics develops in vivo base editing therapeutics for cardiovascular disease using LNP delivery, directly comparable to Addition's cardiometabolic/obesity programs and PRINT's in vivo LNP-based approach. Both target durable single-dose treatments for chronic metabolic conditions.
• Prime Medicine: Prime Medicine develops prime editing technology for precise genomic corrections across a broad range of genetic diseases, using similar plug-and-play platform philosophy to Addition's PRINT. Both companies target rare and chronic diseases with potentially one-time curative approaches.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare disease company with approved Fabry disease enzyme replacement therapy (Fabrazyme), making it directly comparable to Addition's Fabry PRINT program. BioMarin's VP of Operations at Addition (Grady Snyder) previously held roles at BioMarin, indicating deep familiarity with the Fabry competitive landscape.
• Moderna: Moderna is a leading mRNA therapeutics company with proven LNP delivery technology and extensive manufacturing infrastructure. As Addition's leadership includes former Moderna executives (CSO Francine Gregoire), Moderna represents the established mRNA/LNP incumbent whose delivery platform Addition leverages for PRINT.

Emerging players

• Metagenomi: Metagenomi is a preclinical gene editing company developing novel CRISPR-based tools and therapeutics. Addition's VP Greg Cost previously held scientific leadership roles at Metagenomi, indicating technical overlap in novel gene editing/insertion approaches for genetic medicine.

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/addition-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Addition Therapeutics